Clik here to view.
冠科生物新发表的论文详细介绍了体外3D类器官与匹配的PDX在临床相关肿瘤药物开发中的应用
圣迭戈 (美国商业资讯)–JSR Life Sciences旗下的合同研究组织(CRO)冠科生物(Crown Bioscience)日前发布了题为“PDX源性类器官模型在肿瘤学药物发现和开发中的转化和临床意义”的综述文章。...
View ArticleClik here to view.
クラウン・バイオサイエンスの新論文では、マッチング PDXによるIn Vitro 3Dオルガノイドの臨床的に意義のある抗がん剤開発への適用を詳述
サンディエゴ （ビジネスワイヤ） — JSRライフサイエンス傘下企業で医薬品開発業務受託機関（CRO）のクラウン・バイオサイエンスは、「抗がん剤の創薬・開発におけるPDX由来オルガノイドモデルの橋渡し的かつ臨床的な意義」（Translational and Clinical Relevance of PDX-Derived Organoid Models in Oncology Drug...
View ArticleClik here to view.
ImmuneOncia Announces Phase 2 Results of PD-L1 Immune Checkpoint Inhibitor at...
SEONGNAM, South Korea ImmuneOncia (CEO Heung Tae Kim) announced the results of its Phase 2 NK/T-cell lymphoma clinical trial of IMC-001, a PD-L1 monoclonal antibody, at the Asian Congress of the...
View ArticleClik here to view.
MEI Pharma and Kyowa Kirin Announce Discontinuation of Zandelisib Development...
SAN DIEGO & TOKYO MEI Pharma, Inc. (Nasdaq: MEIP), a pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a Japan-based...
View ArticleClik here to view.
MTTI Receives Chinese Patent for EVATHERA Technology
WEST CHESTER, Pa. Molecular Targeting Technologies, Inc. (MTTI) announces the issuance of Chinese Patent CN109153641B covering MTTI’s lead radiotherapeutic product, EBTATE™ and others in its...
View ArticleClik here to view.
Delta-Fly Pharma, Inc. is granted Orphan Drug Designation by US Food and Drug...
TOKUSHIMA, Japan Delta-Fly Pharma, Inc. announces that DFP-10917, a leading pipeline of the company, is granted Orphan Drug Designation (ODD) by US Food and Drug Administration (FDA) for the...
View ArticleClik here to view.
ENHERTU® Achieved Statistically Significant Overall Survival Reducing the...
TOKYO & MUNICH, Germany & BASKING RIDGE, N.J. Updated results from the DESTINY-Breast03 phase 3 trial (Abstract #GS2-02) showed that ENHERTU® (trastuzumab deruxtecan) demonstrated a...
View ArticleClik here to view.
Exscientia在ESMO免疫肿瘤学年度大会上展示针对EXS-21546的新型免疫肿瘤学生物标志物
奥地利维也纳和英格兰牛津 (美国商业资讯)–Exscientia plc (Nasdaq: EXAI)今天强调了新数据，以识别更有可能对其A2A受体拮抗剂EXS-21546...
View ArticleClik here to view.
Kite and Daiichi Sankyo Announce Changes to YESCARTA® CAR T-Cell Therapy...
SANTA MONICA, Calif. & TOKYO Kite Pharma, Inc., a Gilead Company, (hereafter Kite) and Daiichi Sankyo Co., Ltd. (hereafter, Daiichi Sankyo) today jointly announced the revision of their 2017...
View ArticleClik here to view.
エクセンシア、ESMO免疫腫瘍学会の年次総会でEXS-21546用の新規がん免疫療法バイオマーカーを発表
オーストリア・ウィーン & 英オックスフォード （ビジネスワイヤ） — エクセンシア（Nasdaq:...
View ArticleClik here to view.
NRDL Inclusion Offers Substantial Opportunities for Innovative, Clinically...
WALTHAM, Mass. Trinity Life Sciences, a leader in global life sciences commercialization solutions, reports that inclusion on the National Reimbursement Drug List (NRDL) offers substantial...
View ArticleClik here to view.
Bertis Announces Research Results of AI-based Disease Diagnosis Model in the...
SEONGNAM, South Korea Bertis, a proteomics-based precision medicine technology development company (CEOs Dong-young Noh, Seung-man Han), announced research results of AI-based disease diagnosis...
View ArticleClik here to view.
Datopotamab Deruxtecan Showed Encouraging and Durable Efficacy in Patients...
TOKYO & MUNICH & BASKING RIDGE, N.J. Initial results from the TROPION-PanTumor01 phase 1 trial of datopotamab deruxtecan (Dato-DXd) showed encouraging and durable efficacy in patients with...
View ArticleClik here to view.
知临集团宣布发行 2023 年到期的 300 万美元可转换票据
纽约、伦敦和巴黎 (美国商业资讯)– 知临集团有限公司（纳斯达克股票代码：APM，巴黎泛欧证券交易所股票代码：APM）（“知临集团”或“知临”），一家致力于满足肿瘤、自身免疫性疾病和传染病领域未被满足的医疗需求的临床阶段生物制药公司，今天宣布私募发售本金总额为300万美元 的2023年到期的可转换票据（“票据”），将用作公司日常运营和临床计划资金的一部分。 该票据将由Aenco...
View ArticleClik here to view.
Takeda to Present Data at 64th American Society of Hematology (ASH) Annual...
OSAKA, Japan & CAMBRIDGE, Mass. Takeda (TSE:4502/NYSE:TAK) today announced that it will present 15 company-sponsored abstracts at the 64th American Society of Hematology (ASH) Annual Meeting...
View ArticleClik here to view.
Orum Therapeutics Presents Positive Preclinical Data of ORM-6151, a...
BOSTON & DAEJEON, South Korea Orum Therapeutics, a private biotechnology company pioneering the development of tumor-directed targeted protein degraders (TPDs), today announced the presentation...
View ArticleClik here to view.
SaVia Health Raises $8.5 Million Seed Round to Optimize Patient Care Pathways
SALT LAKE CITY SaVia Health, a clinician-led healthcare SaaS company that creates and embeds patient care processes alongside electronic medical records (EMR), announced it raised an $8.5 million...
View ArticleClik here to view.
GIセルがオプティアム・バイオテクノロジーズと契約を締結
韓国・城南 （ビジネスワイヤ） — GIセルは本日、オプティアム・バイオテクノロジーズ株式会社（日本）と研究ライセンス／オプション契約を締結したと発表しました。契約に従い、オプティアム・バイオテクノロジーズはGIセルに対し、オプティアム・バイオテクノロジーズのEumbody...
View ArticleClik here to view.
GI CELL Enters Agreement with Optieum Biotechnologies
SEONGNAM, South Korea GI CELL, Inc. announced today that it has entered into a research license and option agreement with Optieum Biotechnologies, Inc. (Japan). Under the agreement, Optieum...
View ArticleClik here to view.
武田将在美国血液学会(ASH)第64届年会上呈报数据，彰显对血液系统癌症和其他血液病患者的承诺
日本大阪和马萨诸塞州剑桥 (美国商业资讯)–武田(TSE:4502/NYSE:TAK)今天宣布，将于2022年12月10日至13日在新奥尔良召开的美国血液学会(ASH)第64届年会上呈报15篇公司赞助的摘要。武田的最新研究侧重于改善血液病患者的长期转归。 武田的呈报将包括口头报告会，届时将详细介绍3期OPTIC试验的三年更新结果，展示ICLUSIG®...
View Article